Lakewood-Amedex Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lakewood-Amedex Biotherapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 1.2 times its market value (net debt). Lower than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-1.3×Operating cash was negative last year, while some debt falls due within a year.
Higher than 65% of Healthcare companies in United States.
Cash Cushion Ratio
1.2× debtDebt, after subtracting cash, is 1.2 times its market value (net debt).
Lower than 96% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Lakewood-Amedex Biotherapeutics, Inc. made a loss over the last year. Lakewood-Amedex Biotherapeutics, Inc. owes $0.13 for every $1 it owns. Lakewood-Amedex Biotherapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossLakewood-Amedex Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.27The share price is 0.27 times Lakewood-Amedex Biotherapeutics, Inc.'s book value per share, lower than 97% of Healthcare companies in United States.
Market cap
$1 MThe total market value of all of Lakewood-Amedex Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$4 MWhat Lakewood-Amedex Biotherapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.83Net worth divided by the number of shares. The share price of $0.49 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-402.8%Lakewood-Amedex Biotherapeutics, Inc. lost 402.8% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
Owes vs Owns
0.13×Lakewood-Amedex Biotherapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Dividend yield
NoneLakewood-Amedex Biotherapeutics, Inc. does not currently pay a dividend.
Profit growth
LossLakewood-Amedex Biotherapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredLakewood-Amedex Biotherapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtLakewood-Amedex Biotherapeutics, Inc. had $1 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Lakewood-Amedex Biotherapeutics, Inc.: $1 M ÷ $4 M (30 Jun 2026) = 0.3.
What is Lakewood-Amedex Biotherapeutics, Inc.'s return on equity?
Lakewood-Amedex Biotherapeutics, Inc. lost 402.8% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
How much does Lakewood-Amedex Biotherapeutics, Inc. owe compared with what it owns?
Lakewood-Amedex Biotherapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Does Lakewood-Amedex Biotherapeutics, Inc. pay a dividend?
No. Lakewood-Amedex Biotherapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.